Apr 01, 2020 16:23 JST

Source: Eisai

Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China

TOKYO, Apr 01, 2020 - (JCN Newswire) - Eisai Co., Ltd. and Seikagaku announced today that the companies have entered into an agreement for the co-development and marketing alliance in China for SI-613 (diclofenac conjugated sodium hyaluronate), a therapeutic agent for osteoarthritis discovered by Seikagaku.

On the basis of this agreement, the companies will jointly develop SI-613 in China for a treatment of knee osteoarthritis. After obtaining approval, Seikagaku will supply products to Eisai, and Eisai will be responsible for distribution. The companies will cover an equal share of the development cost, and Eisai will pay Seikagaku the upfront payment, and development as well as sales milestones.

Osteoarthritis is a disease caused by the articular cartilage damage due to aging and other factors, leading to inflammation and pain, which result in impaired quality of life (QOL). Knee osteoarthritis is one of the most frequent cases among thereof, and the number of symptomatic patients with knee osteoarthritis in China is estimated to be approximately 47 million(1), and it is anticipated that the number will continue to increase as the population ages.

SI-613 is diclofenac conjugated sodium hyaluronate created by Seikagaku using their proprietary drug-binding technology to chemically bond hyaluronic acid and diclofenac (an anti-inflammatory drug).

This material has the analgesic and anti-inflammatory effects of diclofenac, which is designed to be 23 sustained-released(2) by a drug delivery system(3), in addition to the joint function improving effect of sodium hyaluronate. Hence, it is expected that SI-613 rapidly and continuously reduces the pain and inflammation associated with osteoarthritis.

Under this agreement, Eisai aims to contribute to patients with knee osteoarthritis that is unmet medical needs by utilizing the knowledge and networks that Eisai has cultivated through its China business. Seikagaku will seek to maximize the value of SI-613 in China by leveraging Eisai's business base in China.

Through the development and commercialization of SI-613, the companies will provide new treatment options in China for knee osteoarthritis and contribute to improving the QOL of patients.

(1) For the estimated data regarding the number of patients with knee osteoarthritis
Data of morbidity prevalence rate - The Prevalence of Symptomatic Knee Osteoarthritis in China, ARTHRITIS & RHEUMATOLOGY(2016)
Estimated data calculated from United Nations World Population Estimates - World Population Prospects, URL:http://www.un.org/en/development/desa/population/
(2) Sustained release is a gradual release of the active pharmaceutical ingredients of a drug to achieve a sustained therapeutic effect.
(3) Drug delivery system (DDS) is a technology for the controlled release, targeting, and absorption improvement of drugs.

Source: Eisai
Sectors: BioTech

Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical
March 29 2024 14:51 JST
 
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture
March 29 2024 14:19 JST
 
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024
March 29 2024 13:32 JST
 
Lifenet and Eisai Co-Develop Dementia Insurance "be"
March 21 2024 16:36 JST
 
Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace
March 21 2024 15:10 JST
 
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients
March 06 2024 16:47 JST
 
Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050
February 21 2024 14:26 JST
 
Eisai Selected for 'Human Capital Leaders 2023' and 'Human Capital Management Gold Quality', Recognized as Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
February 20 2024 08:35 JST
 
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan
February 16 2024 08:31 JST
 
Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa
February 01 2024 17:04 JST
 
More Press release >>

Latest Press Release


More Latest Release >>